
Sign up to save your podcasts
Or


Note: this is an updated version of the original article first published on Sep 8. It has been corrected for an error in the number of AI/ML enabled medical devices cleared by the FDA mentioned in the original article.
In this audio brief, we unpack recalls data on AI/ML enabled medical devices to gain insights on emerging vulnerabilities from a risk management point of view.
Here are a few key highlights
* The Landscape: 1,247 FDA cleared AI/ML devices across 155 product codes; 38 recall events identified for a deep dive.
* Recall Severity: Mostly Class II recalls, no Class I recalls.
* Leading Causes:
* Software and algorithm errors (e.g., incorrect dose calculations).
* Data integrity issues (e.g., misfiled or missing images).
* Hardware failures (e.g., loose CT table bolts).
* Labeling & approval lapses (e.g., unapproved software versions).Four-tier, risk-based system; stringent requirements for high-risk systems (including many medical devices); compliance timelines of 1–3 years.
* Trends to Watch:
* High rate of recalls within 12 months of clearance.
* Devices without clinical validation face more, and larger, recalls.
* Public companies account for nearly all recalled units, suggesting market pressures for faster launches without adequate clinical validation.
* Takeaways for stakeholders:
* Manufacturers: Strengthen lifecycle controls, prioritize pre-market validation, enhance post-market vigilance.
* Regulators: Consider time-limited approvals and stronger oversight of high-volume AI devices.
* Clinicians: Validate AI results with clinical judgment—trust but verify.
* Patients: Benefit from innovation but remain vulnerable; safety must remain paramount.
AI in MedTech is transformative but not without risk. The challenge is moving from compliance - driven recall response to active risk mitigation for robust safety and effectiveness.
🎧Listen to the audio brief above for an overview of the AI/ML device recalls, emerging vulnerabilities and trends to watch.
Thanks for reading Let's Talk Risk!. This post is public so feel free to share it.
Note:
This audio brief was prepared using Google NotebookLM, an AI-enabled research tool. Here is the list of resources used in our analysis:
* JAMA: Early Recalls and Clinical Validation Gaps in Artificial Intelligence - Enabled Medical Devices, Research Letter | AI in Health Policy, August 2025.
* AI/ML Recalls Analysis - Unpublished report, created using ChatGPT.
This summary was created using ChatGPT-5 (September 2025) with expert review. It distills publicly available information on FDA-cleared AI/ML-enabled devices and related recall patterns. While reviewed for accuracy and relevance, it does not constitute legal, regulatory, or medical advice. AI in healthcare is a rapidly evolving area, and details may change after publication.
We encourage listeners to interpret these findings in the context of these constraints.
By Casual and informal conversations about practical aspects of medical device risk management.5
22 ratings
Note: this is an updated version of the original article first published on Sep 8. It has been corrected for an error in the number of AI/ML enabled medical devices cleared by the FDA mentioned in the original article.
In this audio brief, we unpack recalls data on AI/ML enabled medical devices to gain insights on emerging vulnerabilities from a risk management point of view.
Here are a few key highlights
* The Landscape: 1,247 FDA cleared AI/ML devices across 155 product codes; 38 recall events identified for a deep dive.
* Recall Severity: Mostly Class II recalls, no Class I recalls.
* Leading Causes:
* Software and algorithm errors (e.g., incorrect dose calculations).
* Data integrity issues (e.g., misfiled or missing images).
* Hardware failures (e.g., loose CT table bolts).
* Labeling & approval lapses (e.g., unapproved software versions).Four-tier, risk-based system; stringent requirements for high-risk systems (including many medical devices); compliance timelines of 1–3 years.
* Trends to Watch:
* High rate of recalls within 12 months of clearance.
* Devices without clinical validation face more, and larger, recalls.
* Public companies account for nearly all recalled units, suggesting market pressures for faster launches without adequate clinical validation.
* Takeaways for stakeholders:
* Manufacturers: Strengthen lifecycle controls, prioritize pre-market validation, enhance post-market vigilance.
* Regulators: Consider time-limited approvals and stronger oversight of high-volume AI devices.
* Clinicians: Validate AI results with clinical judgment—trust but verify.
* Patients: Benefit from innovation but remain vulnerable; safety must remain paramount.
AI in MedTech is transformative but not without risk. The challenge is moving from compliance - driven recall response to active risk mitigation for robust safety and effectiveness.
🎧Listen to the audio brief above for an overview of the AI/ML device recalls, emerging vulnerabilities and trends to watch.
Thanks for reading Let's Talk Risk!. This post is public so feel free to share it.
Note:
This audio brief was prepared using Google NotebookLM, an AI-enabled research tool. Here is the list of resources used in our analysis:
* JAMA: Early Recalls and Clinical Validation Gaps in Artificial Intelligence - Enabled Medical Devices, Research Letter | AI in Health Policy, August 2025.
* AI/ML Recalls Analysis - Unpublished report, created using ChatGPT.
This summary was created using ChatGPT-5 (September 2025) with expert review. It distills publicly available information on FDA-cleared AI/ML-enabled devices and related recall patterns. While reviewed for accuracy and relevance, it does not constitute legal, regulatory, or medical advice. AI in healthcare is a rapidly evolving area, and details may change after publication.
We encourage listeners to interpret these findings in the context of these constraints.

92 Listeners

21 Listeners

0 Listeners